---
title: "Strategic Developments and Partnerships Boost Formycon AG’s Growth Prospects and Support Buy Rating"
description: "Formycon AG's growth prospects are bolstered by strategic developments, including the resolution of patent disputes with Regeneron Pharmaceuticals, allowing for the anticipated U.S. launch of the Eyle"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260036781.md"
published_at: "2025-10-06T10:16:08.000Z"
---

# Strategic Developments and Partnerships Boost Formycon AG’s Growth Prospects and Support Buy Rating

> Formycon AG's growth prospects are bolstered by strategic developments, including the resolution of patent disputes with Regeneron Pharmaceuticals, allowing for the anticipated U.S. launch of the Eylea biosimilar FYB203 in Q4 2026. Partnerships, like the one with Horus Pharma, enhance market penetration. The ongoing Dahlia trial for FYB206 further supports a Buy rating, with analysts like Yi Chen and Kepler Capital maintaining positive outlooks and price targets.

Yi Chen’s rating is based on several strategic developments surrounding Formycon AG. The resolution of patent disputes with Regeneron Pharmaceuticals regarding the Eylea biosimilar FYB203 has paved the way for its anticipated U.S. launch in the fourth quarter of 2026, providing a clear commercial timeline. This settlement not only resolves legal uncertainties but also enhances investor confidence in the company’s future prospects.  
Additionally, Formycon’s strategic partnerships, such as the agreement with Horus Pharma for commercialization in selected European countries, are expected to maximize market penetration. The dual-brand strategy in Europe, combined with Formycon’s role in organizing the supply chain, positions the company to capitalize on its biosimilar products effectively. Furthermore, the ongoing Dahlia trial for FYB206 and its potential market entry post-2029 add to the company’s growth potential, supporting the Buy rating.

According to TipRanks, Chen is an analyst with an average return of \-4.7% and a 43.61% success rate. Chen covers the Healthcare sector, focusing on stocks such as VolitionRX, Anixa Biosciences, and RegenXBio.

In another report released on October 2, Kepler Capital also maintained a Buy rating on the stock with a €50.00 price target.

### Related Stocks

- [FYB.DE - Formycon AG](https://longbridge.com/en/quote/FYB.DE.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Formycon AG Signs Exclusive Licensing Deal with Lotus for Keytruda Biosimilar in Asia-Pacific | Formycon AG has signed an exclusive licensing agreement with Lotus Pharmaceutical for the commercialization of its Keytr | [Link](https://longbridge.com/en/news/275555295.md) |
| FDA Approves Formycon AG’s Nufymco Biosimilar for US Market | Formycon AG has received FDA approval for Nufymco®, a biosimilar to Lucentis®, for all approved indications in the US. Z | [Link](https://longbridge.com/en/news/270617772.md) |
| Godavari Biorefineries Dec-Quarter Consol PAT 82.5 Million Rupees | Godavari Biorefineries Ltd :GODAVARI BIOREFINERIES DEC-QUARTER CONSOL PAT 82.5 MILLION RUPEESGODAVARI BIOREFINERIES LTD  | [Link](https://longbridge.com/en/news/275909082.md) |
| Next Biometrics Secures Order For Fap20 | Next Biometrics Group ASA :NEXT BIOMETRICS SECURES NOK 3.5 MILLION PURCHASE ORDER FOR NEXT BASALT, FAP20 FROM AN EXISTIN | [Link](https://longbridge.com/en/news/276065033.md) |
| Formycon AG: Strategic Advancements and Market Opportunities Drive Buy Rating | Yi Chen has assigned a Buy rating to Formycon AG, citing the successful launch of its ranibizumab biosimilar, FYB201, in | [Link](https://longbridge.com/en/news/262273021.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.